Navigation Links
Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
Date:10/4/2010

SAN DIEGO, Oct. 4 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced the schedule of its upcoming Contrave® (naltrexone sustained release (SR)/bupropion SR) presentations taking place at the 28th Annual Scientific Meeting of The Obesity Society. This meeting will be held at the San Diego Convention Center, October 8-12, 2010.Sunday, October 10:  Embargo Lifts October 10 at 12:30 p.m. PTPoster Presentation
Abstract: 478-P
Presenter: Louis Aronne, M.D., New York Weill Cornell-Columbia Presbyterian Hospital, New York, NY
Title: "Naltrexone SR/Bupropion SR Combination Therapy Reduced Weight and Improved Markers of Cardiometabolic Risk: A Pooled Analysis of Two Phase 3, 56-Week, Double-Blind, Placebo-Controlled Studies"
Time: 12:30 – 1:30 p.m. PT
Location: Hall H
Poster Presentation
Abstract: 480-P
Presenter: Ken Fujioka, M.D., Scripps Clinic, La Jolla, CA
Title: "Naltrexone SR/Bupropion SR Combination Therapy Improves Control of Eating and Reduces Food Cravings in Overweight/Obese Subjects"
Time: 12:30 – 1:30 p.m. PT
Location: Hall H
Poster Presentation
Abstract: 482-P
Presenter: F. Xavier Pi-Sunyer, M.D., St. Luke's-Roosevelt Hospital and Columbia University, New York, NY
Title: "Naltrexone SR/Bupropion SR Combination Therapy Had No Effect on Depression or Suicidal Ideation: A Pooled Analysis From the Contrave Obesity Research Program"
Time: 12:30 – 1:30 p.m. PT
Location: Hall H

Poster Presentation
Abstract: 479-P
Presenter: Raymond A. Plodkowski, M.D., University of Nevada School of Medicine, Reno, NV
Title: "COR I: Naltrexone SR/Bupropion SR Combination Therapy Reduced Weight and Improved Weight-Related Quality of Life in a Phase 3, 56-Week, Double-Blind, Placebo-Controlled Study"
Time: 12:30 – 1:30 p.m. PT
Location: Hall H
Poster Presentation
Abstract: 481-P
Presenter: Susan L. McElroy, M.D., Lindner Center of Hope, Mason, OH
Title: "Reduced Depressive Symptoms and Weight loss in Depressed Overweight/Obese
Subjects Completing 24 Weeks of Open Label Therapy with Naltrexone SR/Bupropion SR"
Time: 12:30 – 1:30 p.m. PT
Location: Hall H
Poster Presentation
Abstract: 499-P
Presenter: Domenica Rubino, M.D., Washington Center for Weight Management & Research, Arlington, VA
Title: "Naltrexone SR/Bupropion SR Combination (NB) Therapy Shifts Subjects From the Obese to the Non-obese Body Mass Index (BMI) Classes—From the COR-II Phase 3, Double-blind, Placebo-controlled, 56-week Study"
Time: 12:30 – 1:30 p.m. PT
Location: Hall HAbout Orexigen TherapeuticsOrexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company has filed an NDA with the FDA for its lead investigational product, Contrave®. The Company's second product, Empatic™, has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at http://www.Orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Present at 9th Annual BIO Investor Forum
2. Pepscan Therapeutics Announces Establishment of Scientific Advisory Board
3. Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
4. PTC Therapeutics Awarded $1.6 Million FDA Orphan Drug Grant to Support an Ongoing Phase 3 Study in Cystic Fibrosis
5. Talecris Biotherapeutics GmbH Awards Winners of the 7th Annual European ALTA Research Fellowship at 2010 ERS Meeting
6. Cell Therapeutics, Inc. Reports Outcome of Annual Meeting of Shareholders
7. Protalix BioTherapeutics Names Tzvi Palash Chief Operating Officer
8. Reportlinker Adds Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
9. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
10. Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange
11. Reportlinker Adds Protein Kinase Therapeutics in Oncology - Where to Commercialize?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... McLean, VA (PRWEB) , ... February 06, 2016 , ... ... enrichment session, cost-free, for middle and high school teachers on Wednesday February 10, 2016. ... be held at the Smithsonian-Mason School of Conservation, located at 1500 Remount Road in ...
(Date:2/6/2016)... ... February 06, 2016 , ... Contact:, Abby Mitchell, Communications Manager, ... Education Sponsors Teacher Training Program , Bite of Science Dinner Event to Strengthen ... Excellence in Education (CEE) will sponsor a Bite of Science professional enrichment session, ...
(Date:2/5/2016)... MANASSAS, Va. , Feb. 5, 2016 ... organization, is poised to assist the medical and life ... concerns around Zika Virus infection.   CDC ... --> Zika virus is a single-stranded ... also includes the West Nile, Dengue and Chikungunya Viruses. ...
(Date:2/5/2016)... CHAPEL HILL, N.C. , Feb. 5, 2016 /PRNewswire/ ... a key role for a host of launch activities ... The importance of this launch activity is especially high ... are specialists. Best Practices and the Role ... study will help companies focused on oncology therapies find ...
Breaking Biology Technology:
(Date:2/2/2016)... 2, 2016  Based on its recent analysis ... recognizes US-based Intelligent Retinal Imaging Systems (IRIS) with ... for New Product Innovation. IRIS, a prominent cloud-based ... America , is poised to set the ... retinopathy market. The IRIS technology presents superior price-performance ...
(Date:1/28/2016)... Synaptics (NASDAQ: SYNA ), a leading developer of ... ended December 31, 2015. --> ... increased 2 percent compared to the comparable quarter last year to ... was $35.0 million, or $0.93 per diluted share. ... first quarter of fiscal 2016 grew 9 percent over the prior ...
(Date:1/22/2016)... DUBLIN , January 22, 2016 ... has announced the addition of the  ... to their offering. --> ... of the  "Global Behavioral Biometric Market ... --> Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ...
Breaking Biology News(10 mins):